“We believe this growth dynamic will lead to significant accretion over time.”

In context

“. And I get that the deal is modest in size, and you don't wanna give some of the financial metrics. But you know, 80% of the purchase price is allocated to goodwill. That's not a trivial amount on a $5 billion deal. And I suspect Brex is not profitable. And you can correct me if that is the wrong assumption. To use here. You do have $950 million of transaction costs and incremental investments. Is it fair to say then that the deal at least initially will be EPS dilutive, intangible book dilutive, if even at a modest amount. And, obviously, overall, you know, value accretive to Capital One Financial Corporation. Richard Fairbank: So Saul, in isolation, Brex will result in earnings dilution initially. As we're buying a business with a growth rate that is multiples of industry growth rates. We believe this growth dynamic will lead to significant accretion over time. Saul Martinez: Okay. Alright. Fair enough. And then I guess just to follow-up here is you mentioned you expect to change in the expected pace of your quarterly share repurchases, which was $2.5 billion. Is that I mean, is that a fair assumption? Or is that is it fair to think that that's sort of a decent cadence for buybacks at least, you know, at least as we stand here today. Andrew Young: So let me clarify the language a bit, which is we're saying that the Brex transaction itself will take down our capital by, I think, a little more than 40 basis points. So a meaningful amount, but certainly not enough to influence our thinking about near-term repurchases. So the point we were making is it's just not going to alter our approach to repurchases. And so, you know, we last quarter that our”